Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02065791
Recruitment Status : Active, not recruiting
First Posted : February 19, 2014
Last Update Posted : March 12, 2018
The George Institute for Global Health, Australia
Information provided by (Responsible Party):
Janssen Research & Development, LLC